Karyopharm Therapeutics Q2 2022 Financial Results & Business Update

Karyopharm Therapeutics presented second quarter 2022 financial results and business updates on August 4, 2022, featuring commercial highlights for XPOVIO and pipeline developments for selinexor and eltanexor. The presentation includes financial guidance, drug development updates, and forward-looking statements regarding commercialization efforts in multiple myeloma and diffuse large B-cell lymphoma.